Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) shares traded up 1.3% during mid-day trading on Monday . The stock traded as high as $1.60 and last traded at $1.57. 62,855 shares traded hands during trading, a decline of 91% from the average session volume of 711,689 shares. The stock had previously closed at $1.55.
Salarius Pharmaceuticals Stock Down 5.1 %
The firm has a market cap of $2.15 million, a price-to-earnings ratio of -0.18 and a beta of 0.92. The company’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.89.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
See Also
- Five stocks we like better than Salarius Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- How to Invest in Small Cap Stocks
- 2 Drone Stocks Surging from Increased Media Attention
- Following Congress Stock Trades
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
